Background: Population-based data on the percentage of colorectal cancer (CRC) patients with synchronous peritoneal carcinomatosis (PC) being treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are currently lacking. The current population-based study describes trends in the use of CRSeHIPEC in the Netherlands, one of the first countries where CRS and HIPEC was introduced. Methods: All patients diagnosed with synchronous PC of CRC between 2005 and 2012 were extracted from the Netherlands Cancer Registry (n ¼ 4623). Patients with primary appendiceal cancer were excluded resulting in a study population of 4430 patients. Trends in the use of CRSeHIPEC over time were analyzed by means of a CochraneeArmitage trend test. Survival proportions were calculated as the time between diagnosis and date of death or last follow-up (January 2014). Results: Of the total 4430 patients with synchronous PC, 297 (6.4%) underwent treatment with CRSeHIPEC. The proportion of colorectal PC patients receiving CRSeHIPEC increased significantly over time from 3.6% in 2005e2006 to 9.7% in 2011e2012 (p < 0.0001). Overall median survival (MS) for patients treated with CRSeHIPEC was 32.3 months, whereas MS rates were respectively 12.6, 6.1 and 1.5 for months palliative chemotherapy with/without surgery, palliative surgery and best supportive care. Conclusion: The proportion of patients diagnosed with synchronous PC from CRC treated with CRSeHIPEC has increased significantly over time and currently almost 10% of PC patients are treated with CRSeHIPEC. Median survival in this population based group is 32.3 months.

, , ,
doi.org/10.1016/j.ejso.2015.01.018, hdl.handle.net/1765/89537
European Journal of Surgical Oncology
Department of Public Health

Razenberg, L., van Gestel, Y., Creemers, G.-J., Verwaal, V. J., Lemmens, V., & de Hingh, I. (2015). Trends in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of synchronous peritoneal carcinomatosis of colorectal origin in the Netherlands. European Journal of Surgical Oncology, 41(4), 466–471. doi:10.1016/j.ejso.2015.01.018